Quick Answer
GeneDx Holdings Corp. reported Revenue (ASC 606) of $427.54 million for fiscal year 2025.
GeneDx Holdings Corp. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $427.54M | +40.0% |
| 2024 | $305.45M | +50.8% |
| 2023 | $202.57M | -13.7% |
| 2022 | $234.69M | +10.6% |
| 2021 | $212.19M | +18.3% |
| 2020 | $179.32M | -8.6% |
| 2019 | $196.17M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $116.74M | +51.9% | +13.7% |
| June 30, 2025 | $102.69M | +45.6% | +17.9% |
| March 31, 2025 | $87.11M | +39.6% | +13.3% |
| September 30, 2024 | $76.87M | +44.2% | +9.0% |
| June 30, 2024 | $70.51M | +44.8% | +13.0% |
| March 31, 2024 | $62.42M | +44.7% | +17.1% |
| September 30, 2023 | $53.30M | -36.0% | +9.4% |
| June 30, 2023 | $48.71M | +34.7% | +12.9% |
- GeneDx Holdings Corp. showed an increase of +40.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2019–2025 period, GeneDx Holdings Corp.’s revenue (asc 606) has grown by 117.9% (from $196.17 million to $427.54 million).
- The most recent figure is from GeneDx Holdings Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: